While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates ...

Why is there still a lack of diversity in clinical trials? Shelli Pavone: Unfortunately equity and healthcare have ...

John Hood, CEO, Endeavor BioMedicines discusses a potential timeline on availability of ENV-101 for patients with IPF and further validation of the treatment's safety profile.

Data from the Phase III trial program found that AXS-05 demonstrated statistically significant efficacy in treating Alzheimer disease agitation. Axsome Therapeutics announced the successful completion ...

The FDA has granted Fast Track Designation to Star Therapeutics’ VGA039, an investigational monoclonal antibody targeting Protein S for the treatment of von Willebrand disease (VWD). According to the ...

In the race to bolster pipelines and drive growth, biopharma manufacturers are reexamining traditional practices and reimagining market research protocols. Biopharma business development and licensing ...

The FDA has issued a draft guidance outlining recommendations for the use of artificial intelligence (AI) to support regulatory decisions regarding the safety, efficacy, or quality of drugs and ...

The pharmaceutical industry continues to experiment with different use cases for AI. While the technology has garnered plenty of headlines over the past two years, the industry has yet to produce a ...

The campaign is focused on the drug’s ability to fight hunger cravings. For many people, losing weight is more difficult that just reducing their caloric intake. While doing so will result in weight ...